Comparative Evaluation of Mesenchymal Stromal Cells from Umbilical Cord and Amniotic Membrane in Xeno-free Conditions

Overview

Journal BMC Cell Biol

Publisher Biomed Central

Specialty Cell Biology

Date 2018 Dec 15

PMID 30545286

Citations 6

Authors

Yongxu Mu

Xiaoyun Wu

Zhiming Hao

Affiliations

Soon will be listed here.

Abstract

Background: Within the past years, umbilical cord (UC) and amniotic membrane (AM) expanded in human platelet lysate (PL) have been found to become increasingly candidate of mesenchymal stromal cells (MSCs) in preclinical and clinical studies. Different sources of MSCs have different properties, and lead to different therapeutic applications. However, the similarity and differences between the AMMSCs and UCMSCs in PL remain unclear.

Results: In this study, we conduct a direct head-to-head comparison with regard to biological characteristics (morphology, immunophenotype, self-renewal capacity, and trilineage differentiation potential) and immunosuppression effects of AMMSCs and UCMSCs expanded in PL. Our results indicated that AMMSCs showed similar morphology, immunophenotype, proliferative capacity and colony efficiency with UCMSCs. Moreover, no significantly differences in osteogenic, chondrogenic and adipogenic differentiation potential were observed between the two types of cells. However, AMMSCs exhibited higher PGE expression and IDO activity compared with UCMSCs when primed by IFN-γ and (or) TNF-α induction, and AMMSCs showed a higher inhibitory effect on PBMCs proliferation than UCMSCs.

Conclusion: The results suggest that AMMSCs expanded in PL showed similar morphology, immunophenotype, self-renewal capacity, and trilineage differentiation potential with UCMSCs. However, AMMSCs possessed superior immunosuppression effects in comparison with UCMSCs. These results suggest that AMMSCs in PL might be more suitable than UCMSCs for treatment of immune diseases. This work provides a novel insight into choosing the appropriate source of MSCs for treatment of immune diseases.

Citing Articles

Cell Sheet Technology as an Engineering-Based Approach to Bone Regeneration.

You Q, Lu M, Li Z, Zhou Y, Tu C Int J Nanomedicine. 2022; 17:6491-6511.

PMID: 36573205 PMC: 9789707. DOI: 10.2147/IJN.S382115.

Comparative Analysis of the Therapeutic Effects of Amniotic Membrane and Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Type 2 Diabetes.

Wang Z, Li H, Fang J, Wang X, Dai S, Cao W Stem Cell Rev Rep. 2022; 18(3):1193-1206.

PMID: 35015214 PMC: 8749914. DOI: 10.1007/s12015-021-10320-w.

Research Progress on the Treatment of Premature Ovarian Failure Using Mesenchymal Stem Cells: A Literature Review.

Wang J, Liu W, Yu D, Yang Z, Li S, Sun X Front Cell Dev Biol. 2021; 9:749822.

PMID: 34966738 PMC: 8710809. DOI: 10.3389/fcell.2021.749822.

Human amnion-derived mesenchymal stem cells attenuate xenogeneic graft-versus-host disease by preventing T cell activation and proliferation.

Tago Y, Kobayashi C, Ogura M, Wada J, Yamaguchi S, Yamaguchi T Sci Rep. 2021; 11(1):2406.

PMID: 33510297 PMC: 7843654. DOI: 10.1038/s41598-021-81916-y.

Serum-Free Medium Enhances the Therapeutic Effects of Umbilical Cord Mesenchymal Stromal Cells on a Murine Model for Acute Colitis.

Wu X, Wu D, Mu Y, Zhao Y, Ma Z Front Bioeng Biotechnol. 2020; 8:586.

PMID: 32671030 PMC: 7332562. DOI: 10.3389/fbioe.2020.00586.

References

Barcia R, Santos J, Filipe M, Teixeira M, Martins J, Almeida J . What Makes Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells Superior Immunomodulators When Compared to Bone Marrow Derived Mesenchymal Stromal Cells?. Stem Cells Int. 2015; 2015:583984. PMC: 4443932. DOI: 10.1155/2015/583984. View

Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, Carobbio A . Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant. 2007; 40(8):785-91. DOI: 10.1038/sj.bmt.1705798. View

Araujo A, Salton G, Furlan J, Schneider N, Angeli M, Laureano A . Comparison of human mesenchymal stromal cells from four neonatal tissues: Amniotic membrane, chorionic membrane, placental decidua and umbilical cord. Cytotherapy. 2017; 19(5):577-585. DOI: 10.1016/j.jcyt.2017.03.001. View

Tarte K, Gaillard J, Lataillade J, Fouillard L, Becker M, Mossafa H . Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood. 2009; 115(8):1549-53. DOI: 10.1182/blood-2009-05-219907. View

Fekete N, Gadelorge M, Furst D, Maurer C, Dausend J, Fleury-Cappellesso S . Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of.... Cytotherapy. 2012; 14(5):540-54. PMC: 3400099. DOI: 10.3109/14653249.2012.655420. View

Squillaro T, Peluso G, Galderisi U . Clinical Trials With Mesenchymal Stem Cells: An Update. Cell Transplant. 2015; 25(5):829-48. DOI: 10.3727/096368915X689622. View

Talwadekar M, Kale V, Limaye L . Placenta-derived mesenchymal stem cells possess better immunoregulatory properties compared to their cord-derived counterparts-a paired sample study. Sci Rep. 2015; 5:15784. PMC: 4623529. DOI: 10.1038/srep15784. View

Galipeau J, Krampera M, Barrett J, Dazzi F, Deans R, DeBruijn J . International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016; 18(2):151-9. PMC: 4745114. DOI: 10.1016/j.jcyt.2015.11.008. View

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

10.

Ng F, Boucher S, Koh S, Sastry K, Chase L, Lakshmipathy U . PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic,.... Blood. 2008; 112(2):295-307. DOI: 10.1182/blood-2007-07-103697. View

11.

Yamahara K, Harada K, Ohshima M, Ishikane S, Ohnishi S, Tsuda H . Comparison of angiogenic, cytoprotective, and immunosuppressive properties of human amnion- and chorion-derived mesenchymal stem cells. PLoS One. 2014; 9(2):e88319. PMC: 3925106. DOI: 10.1371/journal.pone.0088319. View

12.

Eppley B, Woodell J, Higgins J . Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004; 114(6):1502-8. DOI: 10.1097/01.prs.0000138251.07040.51. View

13.

Davies J, Walker J, Keating A . Concise Review: Wharton's Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. Stem Cells Transl Med. 2017; 6(7):1620-1630. PMC: 5689772. DOI: 10.1002/sctm.16-0492. View

14.

Jin H, Bae Y, Kim M, Kwon S, Jeon H, Choi S . Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci. 2013; 14(9):17986-8001. PMC: 3794764. DOI: 10.3390/ijms140917986. View

15.

Bortolotti F, Ukovich L, Razban V, Martinelli V, Ruozi G, Pelos B . In vivo therapeutic potential of mesenchymal stromal cells depends on the source and the isolation procedure. Stem Cell Reports. 2015; 4(3):332-9. PMC: 4375942. DOI: 10.1016/j.stemcr.2015.01.001. View

16.

Sharma R, Pollock K, Hubel A, McKenna D . Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion. 2014; 54(5):1418-37. PMC: 6364749. DOI: 10.1111/trf.12421. View

17.

Murphy M, Blashki D, Buchanan R, Yazdi I, Ferrari M, Simmons P . Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials. 2012; 33(21):5308-16. DOI: 10.1016/j.biomaterials.2012.04.007. View

18.

Wu M, Zhang R, Zou Q, Chen Y, Zhou M, Li X . Comparison of the Biological Characteristics of Mesenchymal Stem Cells Derived from the Human Placenta and Umbilical Cord. Sci Rep. 2018; 8(1):5014. PMC: 5864926. DOI: 10.1038/s41598-018-23396-1. View

19.

Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L . Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints. Cytotherapy. 2013; 15(7):753-9. DOI: 10.1016/j.jcyt.2013.03.005. View

20.

Hemeda H, Giebel B, Wagner W . Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. Cytotherapy. 2014; 16(2):170-80. DOI: 10.1016/j.jcyt.2013.11.004. View